

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/121369/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Da'as, Sahar I., Thanassoulas, Angelos, Calver, Brian, Beck, Konrad, Salem, Rola, Saleh, Alaaeldin, Kontogianni, Iris, Al-Maraghi, Ali, Nasrallah, Gheyath K., Safieh-Garabedian, Bared, Toft, Egon, Nounesis, George, Lai, F A and Nomikos, Michail 2019. Arrhythmogenic calmodulin E105A mutation alters cardiac RyR2 regulation leading to cardiac dysfunction in zebrafish. *Annals of the New York Academy of Sciences* 1448 (1), pp. 19-29. 10.1111/nyas.14033

Publishers page: <http://dx.doi.org/10.1111/nyas.14033>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



MARROW

ANNALS of THE NEW YORK
ACADEMY OF SCIENCES

Arrhythmogenic calmodulin E105A mutation alters cardiac RyR2 regulation leading to cardiac dysfunction in zebrafish

Journal:	<i>MARROW-Ann NY Acad Sci</i>
Manuscript ID	MARROW-062
Manuscript Type:	Original Article
Date Submitted by the Author:	28-Nov-2018
Complete List of Authors:	Da'as, Sahar; Sidra Medicine, Translational Medicine; Hamad Bin Khalifa University, College of Health and Life Sciences Thanassoulas, Angelos ; National Centre for Scientific Research-Demokritos Calver, Brian; Cardiff University Beck, Konrad; Cardiff University Salem, Rola; Qatar University College of Medicine Saleh, Alaaeldin ; Qatar University College of Medicine Kontogianni, Iris; National Centre for Scientific Research-Demokritos Al-Maraghi, Ali; Qatar University College of Medicine Nasrallah, Gheyath; Qatar University; Qatar University, Department of Biomedical Sciences Safieh-Garabedian, Bared; Qatar University College of Medicine Toft, Egon; Qatar University College of Medicine Nounesis, George; National Centre for Scientific Research-Demokritos Lai, F. Anthony; Cardiff University; Qatar University College of Medicine; Qatar University NOMIKOS, MICHAEL; Qatar University College of Medicine
Keywords:	calmodulin, calcium, ryanodine receptor 2, arrhythmia, zebrafish

SCHOLARONE™
Manuscripts

Arrhythmogenic calmodulin E105A mutation alters cardiac RyR2 regulation leading to cardiac dysfunction in zebrafish

Sahar I. Da'as^{1,2}, Angelos Thanassoulas³, Brian L. Calver⁴, Konrad Beck⁴, Rola Salem⁵, Alaaeldin Saleh⁵, Iris Kontogianni³, Ali Al-Maraghi⁵, Gheyath K. Nasrallah^{6,7}, Bared Safieh-Garabedian⁵, Egon Toft⁵, George Nounesis³, F. Anthony Lai^{4,5,6} and Michail Nomikos^{5*}

¹Translational Medicine, Sidra Medicine, Doha, Qatar

²College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar

³National Center for Scientific Research "Demokritos", Aghia Paraskevi, Greece

⁴College of Biomedical & Life Sciences, Cardiff University, Cardiff, UK

⁵College of Medicine, Member of QU Health, Qatar University, Doha, Qatar

⁶Biomedical Research Center, Qatar University, Doha, Qatar

⁷Department of Biomedical Sciences, College of Health Science, Qatar University, Doha, Qatar

*Correspondence to:

Michail Nomikos: mixosn@yahoo.com

College of Medicine, Member of QU Health

Qatar University

Doha, P.O. BOX: 2713, Qatar

Phone: +974 44037846

Short title: Functional analysis of CaM E105A mutation

Keywords: Calmodulin, calcium, ryanodine receptor 2, arrhythmia, long QT syndrome, zebrafish

Abstract

Calmodulin (CaM) is a universal calcium (Ca²⁺)-binding messenger that regulates many vital cellular events. In cardiac muscle, CaM associates with ryanodine receptor 2 (RyR2) and regulates excitation-contraction coupling. Mutations in human *CALM1*, *CALM2*, and *CALM3* genes have been associated with life-threatening heart disorders, such as long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia. A novel *de novo* LQTS-associated missense CaM mutation (E105A) was recently identified in a 6-year-old boy, who experienced an aborted first-episode of cardiac arrest. Herein, we report the first molecular characterization of CaM E105A mutation. Expression of CaM E105A mutant in zebrafish embryos resulted in cardiac arrhythmia and increased heart rate, suggestive to ventricular tachycardia. *In vitro* biophysical and biochemical analysis revealed that E105A confers a deleterious effect on protein stability and a reduced Ca²⁺-binding affinity due to loss of cooperativity. Finally, CaM E105A mutation resulted in a reduced CaM-RyR2 interaction and defective modulation of [³H]ryanodine binding. Our findings suggest that CaM E105A mutation dysregulates normal cardiac function by a complex mechanism involving alterations in both CaM-Ca²⁺ and CaM-RyR2 interactions.

Introduction

Calmodulin (CaM) is a ubiquitous, highly conserved calcium (Ca^{2+})-binding protein that binds and regulates a number of different protein targets, thereby affecting a wide range of vital cellular processes.¹ CaM acts as an intracellular Ca^{2+} sensor, decoding downstream Ca^{2+} signals and by undergoing conformational changes, binds specifically to its multiple protein partners in a Ca^{2+} -dependent manner.² CaM is a relatively small protein composed of 148 amino acids with a with very basic domain architecture. Based on its crystal structure, it consists of two globular domains located at the N- and C- termini (N- and C- lobes), separated by a flexible α -helix, in a dumbbell-resembling conformation. Each lobe consists of two EF hand motifs, with each motif binding one Ca^{2+} ion.³ Thus, the total Ca^{2+} binding capacity of CaM is four Ca^{2+} ions, allowing it to interact with multiple protein targets in both apo-CaM (Ca^{2+} -free CaM) and Ca^{2+} -CaM (Ca^{2+} -loaded CaM) forms. Interestingly, the N- and C-lobes appear to have markedly distinct Ca^{2+} binding characteristics, making the decoding of Ca^{2+} signals a highly complex process.^{4, 5}

In cardiac cells, CaM is known to interact and regulate multiple key proteins involved in excitation-contraction coupling (ECC) and Ca^{2+} homeostasis. These proteins include the cardiac ryanodine receptor type 2 (RyR2), voltage operated potassium (K^+), sodium (Na^+) and L-type Ca^{2+} channels.⁶ The RyR2 is a large transmembrane high conductance Ca^{2+} release channel that mediates Ca^{2+} release from the sarcoplasmic reticulum (SR) to activate cardiac muscle contraction.⁶ RyR2 gating is crucial for the receptor function and is mediated by a number of modulators (including ions, small molecules and proteins), which regulate the exact timing of channel opening or closing.⁷ It is well established that CaM binds to RyR2 stoichiometrically (one CaM per subunit of the homotetrameric RyR2) and inhibits its open probability at both low and high cytosolic Ca^{2+} concentrations. Several studies have proposed that CaM regulation of RyR2 is essential for normal cardiac function.⁸⁻¹⁰

1
2
3 In humans there are three CaM genes (*CALM1*, *CALM2* and *CALM3*), which encode
4 an identical protein and are all expressed in cardiac tissue.^{5,6} A number of recent genetic studies
5 have identified several missense mutations in all three *CALM* genes, in individuals with a
6 family history of severe cardiac disorders and early onset sudden cardiac death.¹¹⁻¹⁶
7
8
9
10
11

12 A recent clinical study reported a case of aborted cardiac arrest in a seemingly healthy
13 6-year-old boy who exhibited profound QT prolongation with an increasing heart rate before
14 the recurrence of polymorphic ventricular tachycardia at a pediatric intensive care unit.¹⁷ The
15 patient had no family history of heart disease, while his parents' ECGs appeared to be normal.
16 Genetic screening revealed a novel de novo missense variation c.A314>C in exon 5 of *CALM1*
17 gene of this patient.¹⁷ This nucleotide change results in the substitution of a conserved glutamic
18 acid (E) with an alanine (A) residue (p.E105A) within the third EF-hand motif in the C-domain
19 of CaM protein.
20
21
22
23
24
25
26
27
28
29
30

31 In the present study, the *in vivo* functional effects of CaM E105A mutation on normal
32 zebrafish embryonic heart function were investigated following human CaM wild type
33 (CaM^{WT}) and CaM E105A mutant ($\text{CaM}^{\text{E105A}}$) complementary RNA (cRNA) microinjection
34 experiments in zebrafish embryos. CaM^{WT} and $\text{CaM}^{\text{E105A}}$ mutant were bacterially expressed
35 and affinity purified as recombinant proteins and their biophysical properties were analyzed by
36 circular dichroism (CD) and thermal denaturation experiments. The Ca^{2+} -binding affinities of
37 both the N- and C-lobes of $\text{CaM}^{\text{E105A}}$ mutant were determined by monitoring the intrinsic
38 tyrosine and phenylalanine fluorescence and compared to those of CaM^{WT} . Furthermore, co-
39 immunoprecipitation experiments of native RyR2 with CaM^{WT} and $\text{CaM}^{\text{E105A}}$ mutant were
40 employed to compare their relative RyR2-binding affinities. Finally, the functional effect of
41 CaM E105A mutation on the RyR2 activity was examined with isolated SR membranes via a
42 [³H]ryanodine binding assay. Our findings suggest that the arrhythmogenic CaM E105A
43 mutation dysregulates the normal embryonic heart function in zebrafish by a complex
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 mechanism, which involves defects in both CaM-Ca²⁺ binding and CaM-RyR2 interaction and
4
5 regulation.
6
7
8
9

10 **Material and Methods**

11
12 A detailed description of methods is provided in the Supplementary Material and Methods
13
14 section.
15
16
17
18
19

20 **Results**

21 **Expression of CaM^{E105A} mutant in zebrafish embryos mimics patient's ventricular** 22 23 **tachycardia** 24 25

26
27 To investigate any potential *in vivo* functional effects of the LQTS-associated CaM
28
29 E105A mutation on zebrafish embryonic heart function, we generated and injected synthetic
30
31 cRNA corresponding to CaM^{WT} and CaM^{E105A} mutant into zebrafish embryos. Injected
32
33 zebrafish embryos were then raised up to 72 hours post-fertilization (hpf) and their cardiac
34
35 function was assessed. As shown in Figure 1A (left panel), expression of CaM^{WT} and CaM^{E105A}
36
37 mutant in zebrafish embryos did not affect normal embryo development, as neither gross
38
39 morphological changes nor difference in the survival rate were observed in comparison to the
40
41 control group (uninjected zebrafish embryos). However, we observed a slight change in the
42
43 heart morphology of CaM^{E105A}-injected zebrafish with ~31.5% embryos exhibiting extended
44
45 cardiac chambers (Figure 1A, right panel). The average heart rate was significantly increased
46
47 in this group at an average of 160.5 beats per minute (bpm), (**p = 0.007) when compared to
48
49 the control group at 152.5 bpm (Figure 1B). Furthermore, cardiac function assessment was
50
51 performed. Analysis of the cardiac activity of zebrafish ventricle revealed that CaM^{E105A}
52
53 mutant-injected zebrafish displayed irregular pattern of heart beating in comparison to the
54
55 median of the CaM^{WT} and control groups (Figure 2). The CaM^{E105A} resulted in increased
56
57
58
59
60

1
2
3 arrhythmic potential in this zebrafish model. Collectively, our data suggest that expression of
4
5 CaM^{E105A} mutant in zebrafish embryos results in cardiac arrhythmia and increased heart rate,
6
7 mimicking the clinical presentation of the reported 6-year-old boy, which displayed increased
8
9 heart rate and ventricular tachycardia.
10
11
12
13
14

15 **E105A mutation alters CaM thermal stability in the presence of Ca²⁺**

16
17 To investigate the effect of E105A mutation on the *in vitro* biophysical and biochemical
18
19 properties of CaM^{WT} protein, CaM^{E105A} mutant was subcloned into the pHSIE plasmid
20
21 expression vector and a bacterial expression system was used to express large quantities of
22
23 recombinant CaM^{WT} and CaM^{E105A} proteins. Expressed recombinant proteins were affinity
24
25 purified, as we have previously described.^{6, 18} Figure 3A shows the affinity-purified untagged
26
27 CaM^{WT} and CaM^{E105A} recombinant proteins analyzed by SDS-PAGE and immunoblot analysis
28
29 using an anti-CaM rabbit monoclonal antibody. For each CaM construct, a single protein band
30
31 with mobility corresponding to the predicted molecular mass (~17.4 kDa) was observed, which
32
33 was also confirmed by the immunoblot detection.
34
35
36

37
38 CD spectra recorded at 4 °C indicated that CaM^{E105A} has the same overall conformation
39
40 as CaM^{WT} both in the absence and presence of Ca²⁺ (Fig. 3BI). In the presence of 1mM EDTA,
41
42 thermal denaturation curves showed only small differences with T_m¹ and T_m² ~46 and 63 °C
43
44 and ΔH_{vH}¹ and ΔH_{vH}² *ca.* -100 and -185 kJ/mol, respectively (Fig. 3BII, III). These values are
45
46 in good agreement with those previously reported for CaM^{WT}.^{19, 20} In the presence of Ca²⁺,
47
48 CaM^{E105A} showed a clear bimodal transition with T_m¹ and T_m² ~58 and 97 °C compared to ~90
49
50 and 120 °C observed for CaM^{WT}, respectively. A similar behavior we had observed for the
51
52 arrhythmogenic CaM^{D130G} mutant in a previous study.⁶
53
54
55
56
57
58
59
60

E105A mutation dramatically alters the Ca²⁺-binding properties of CaM C-domain

Typical normalized fluorescence emission intensity measurements as a function of Ca²⁺ concentration for both CaM^{WT} and CaM^{E105A} are presented in Figures 4A, following changes in the protein N-domain and C-domain respectively. For the C-domain, there is an increase in fluorescence intensity at 320 nm (excitation wavelength: 277 nm) as a function of the free Ca²⁺ concentration in the sample, while for the N-domain the fluorescence intensity decreases at 280 nm (excitation wavelength: 250 nm). Intrinsic calcium-dependent fluorescence intensity changes at these characteristic wavelengths can be used to reliably monitor the occupancy of the EF-hand binding sites in each protein domain.²¹ To analyze the data, results from four independent experiments were fitted using global nonlinear regression to a model-independent two-site Adair function and the results are summarized in Table 1. For CaM^{WT} C-domain, binding sites have an apparent K_d almost 3-fold higher than that of the N-domain binding sites (2.97 vs 8.08 μM respectively). The free energy change that accompanies the binding of two Ca²⁺ at the C-domain binding sites was found to be -63.1 kJ/mol with a cooperative free energy change of -9.8 kJ/mol, while the corresponding values for the N-domain binding sites were -58.2 and -4.3 kJ/mol, respectively. These calculations are in good agreement with earlier studies under the same experimental conditions.^{6, 18} The N-Domain binding sites show no differences between CaM^{WT} and CaM^{E105A} in terms of binding affinity (Figure 4A and Table 1) and binding cooperativity. This is not surprising considering that E105A mutation is located within the C-domain of the CaM protein. Relative to the C-domain binding sites, CaM^{E105A} shows a ~10-fold lower affinity for Ca²⁺ compared to CaM^{WT} (Table 1). Thermodynamic analysis of the free energy changes upon Ca²⁺ binding to the C-domain binding sites, reveals an interesting picture. The free energy change for CaM^{E105A} is similar to that of CaM^{WT} only when one binding site is occupied (-26.6 kJ/mol and -28.4 kJ/mol respectively), while the total free energy change for binding to both C-domain binding sites is significantly reduced (11.3

1
2
3 kJ/mol less). In addition, for the C-domain of CaM^{E105A}, the free energy gained by pairing of
4 the two binding sites (ΔG_c) is 7.6 kJ/mol, less than that of CaM^{WT}. The aforementioned effects
5 can be interpreted as a significant loss of cooperativity between the two binding sites of this
6 domain, leading to its reduced Ca²⁺-binding affinity. Molecular modelling (Figure 4B) based
7 on CaM X-ray structure confirms our observations suggesting that glutamic acid (E) at position
8 105 is directly involved in Ca²⁺-binding of CaM C-domain and its substitution by an alanine
9 (A) residue dramatically alters the cooperativity between the two binding sites of this domain.

20 21 **CaM^{E105A} mutant displays reduced RyR2 interaction and defective modulation of** 22 **[³H]ryanodine binding**

23
24
25
26 It has been demonstrated that RyR2 is the major binding site for CaM along the Z-line
27 in cardiomyocytes and that dissociation of CaM from RyR2 can trigger severe ventricular
28 arrhythmia.^{8, 10} Thus, reduced CaM-RyR2 interaction can result in heart failure. To compare
29 the relative RyR2-binding affinities of CaM^{WT} and CaM^{E105A} we used a co-
30 immunoprecipitation assay, as we have previously described.^{6, 18} Native RyR2 from pig cardiac
31 SR was immunoprecipitated with a purified anti-RyR2 specific antibody in the presence of
32 either recombinant CaM^{WT} or CaM^{E105A} at different Ca²⁺ concentrations. Association of CaM
33 with RyR2 was analyzed by SDS-PAGE electrophoresis and immunoblot analysis using the
34 anti-CaM monoclonal antibody. Densitometric analysis revealed that RyR2 binding to
35 CaM^{E105A} was dramatically decreased (over ~70%) compared to CaM^{WT} at all Ca²⁺
36 concentrations (Figure 5A), suggesting that E105A mutation exhibits a major inhibitory effect
37 on the binding of CaM to RyR2.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
To further investigate the functional effect of this novel cardiac disease-associated CaM
mutation on RyR2 regulation, we performed [³H]ryanodine binding assays.^{6, 18} [³H]ryanodine
binding assay represents a useful biochemical tool to study the action of different modulators

1
2
3 on the RyR2 function, as it has been demonstrated that the binding of [³H]ryanodine to RyR is
4 dependent upon the functional state of the channel. The effect of CaM^{WT} and its corresponding
5 mutants on [³H]ryanodine binding to RyR2 was examined in a range of different Ca²⁺
6 concentrations varying from 10nM to 10μM. As shown in Figure 5B, CaM^{WT} significantly
7 reduced the ryanodine binding compared to control (no added CaM protein). In contrast,
8 inhibition of ryanodine binding to RyR2 by CaM^{E105A} mutant was almost abolished at all high
9 Ca²⁺ concentrations, suggesting impaired or no association of RyR2 with this CaM mutant.
10 These findings support our co-immunoprecipitation experiments that indicated a dramatically
11 reduced RyR2- CaM^{E105A} interaction.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 Discussion

28
29 CaM is one of the most essential cytosolic Ca²⁺ signaling molecules regulating several
30 vital biochemical cascades within eukaryotic cells. CaM is a relatively small protein but
31 displays a high degree of conformational plasticity. Ca²⁺ binding to CaM can induce major
32 conformational changes conferring to CaM the ability to bind to its multiple protein targets
33 (cytosolic or membrane bound) within the cell, regulating their function in a Ca²⁺-dependent
34 manner.² Interestingly, CaM N- and C-lobes display different Ca²⁺-binding affinities and
35 kinetics upon target binding highlighting the complex mechanism that this versatile molecule
36 translates the Ca²⁺ signals to its several protein targets within the cell.^{5, 21}
37
38
39
40
41
42
43
44
45
46
47

48 In cardiac cells, calmodulin is an important regulator of ECC and Ca²⁺ homeostasis
49 through its direct interaction with a number of key proteins, including RyR2, voltage operated
50 potassium, sodium and L-type Ca²⁺ channels.⁶ All the three CaM genes (*CALM1*, *CALM2* and
51 *CALM3*) that encode for an identical protein, expressed in cardiac tissue. Over the last few
52 years, several genetic and clinical reports have identified a number of missense mutations in
53 all three *CALM* genes in individuals with a family history of life-threatening arrhythmogenic
54
55
56
57
58
59
60

1
2
3 cardiac disorders and early onset sudden cardiac death.¹¹⁻¹⁶ A recent genetic report identified a
4 novel *de novo* LQTS-associated missense CaM mutation (E105A) in a 6-year-old boy with no
5 family history of heart disease, who experienced an aborted first-episode of cardiac arrest.¹⁷
6
7

8
9
10 In this study, we employed a zebrafish model to investigate for the first time the *in vivo*
11 functional effects of CaM E105A mutation in a vertebrate model system and more specifically
12 to study its impact on the normal zebrafish embryonic heart function. Zebrafish cRNA
13 microinjection experiments revealed that expression of CaM^{WT} and CaM^{E105A} mutant did not
14 have any effect on the normal embryo development as neither gross morphological changes
15 nor difference in the survival rate were observed in comparison to the control group.
16
17 Interestingly and in contrast with the CaM^{WT}-injected zebrafish, a slight change in the heart
18 morphology was observed in CaM^{E105A}-injected embryos with ~31.5% exhibiting an extended
19 cardiac chamber. Moreover, the expression of CaM^{E105A} mutant in these zebrafish embryos
20 resulted in a specific cardiac phenotype represented in cardiac arrhythmia and an increased
21 heart rate, suggestive to ventricular tachycardia. This observed cardiac phenotype mimicked
22 the human LQTS cardiac phenotype due to abnormal regulation of the ion channels involved
23 in cardiac repolarization. Our molecular modelling, which was based on a CaM X-ray structure,
24 suggested that CaM E105 is directly involved in Ca²⁺-binding and that its substitution by an
25 alanine could lead to alterations of the Ca²⁺-binding properties of CaM C-lobe. This was
26 confirmed by our Ca²⁺-binding studies, which revealed that the C-domain of CaM^{E105A} mutant
27 exhibits a ~10-fold reduced Ca²⁺-binding affinity compared to CaM^{WT}. This was also in
28 agreement with our thermal denaturation experiments, which showed that in the presence of
29 Ca²⁺, E105A mutation confers a deleterious impact on the protein stability. RyR2 is the main
30 binding partner for CaM along the Z-line in cardiomyocytes.^{8, 22} RyR2 is activated by Ca²⁺
31 entry into the cytosol through the sarcolemmal voltage-gated channels and this Ca²⁺ entry
32 activates RyR2, triggering RyR2-mediated Ca²⁺ release resulting in a rise of the free cytosolic
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Ca²⁺ concentration.²³ CaM binding to RyR2 inhibits Ca²⁺ release both at diastolic and systolic
4
5 cytosolic Ca²⁺ concentrations.⁹ It has been proposed that aberrant CaM dissociation from RyR2
6
7 can lead to heart failure.⁸ Our biochemical analysis revealed that CaM E105 mutation
8
9 significantly reduces RyR2-CaM interaction at all Ca²⁺ concentrations, leading to a
10
11 dramatically reduced modulation of [³H]ryanodine binding to RyR2. These observations could
12
13 highlight a potential mechanism on how this CaM mutation can lead to arrhythmogenic cardiac
14
15 disease. A previous study revealed that in zebrafish there are two *ryr2* genes (*ryr2a* and *ryr2b*),
16
17 which are expressed exclusively in developing central nervous system and cardiac tissue,
18
19 respectively.²⁴ It has been previously suggested that in mammals the RyR2 does not contribute
20
21 to the onset of contractile activity at very early embryonic stages.^{24, 25} However, in zebrafish
22
23 cardiac *ryr* gene (*ryr2b*) is expressed exclusively in the developing heart tissue (precardiac
24
25 mesoderm) from 14 hpf, 8 hours prior to the onset of cardiac contraction at 22 hpf, and may
26
27 well contribute to early cardiac development as well as function.²⁴ It is very intriguing how
28
29 various pathogenic CaM mutations impose different arrhythmogenic cardiac phenotypes,
30
31 including CPVT, LQTS and in some cases an overlapping CPVT/LQTS phenotype. This
32
33 suggests that there might be a mechanistic overlap between CPVT and LQTS caused by CaM
34
35 mutations.²⁶ CPVT is characterized by exercise- or stress-induced ventricular arrhythmias,
36
37 which can lead to syncope or sudden cardiac death. Mutations in RyR2 and other auxiliary
38
39 proteins, such as calsequestrin-2 and CaM, have been identified in most CPVT-affected
40
41 patients.²⁶⁻³⁰ On the other hand, LQTS can also affect the resting heart and with increasing
42
43 effect upon adrenergic stimulation.^{26, 31} In contrast to CPVT, LQTS is mainly characterized by
44
45 dysfunction of the sarcolemmal voltage-gated Na⁺, Ca²⁺, and K⁺ channels in control of the
46
47 action potential.²⁶ Interestingly, many previous studies have proposed different molecular
48
49 mechanisms and different CaM targets to explain how CaM mutations lead to arrhythmogenic
50
51 cardiac disease, even within the same arrhythmia type.^{6, 15, 20, 23, 26, 32-35} This could be explained
52
53
54
55
56
57
58
59
60

1
2
3 by the multifunctional nature of CaM and the plethora of targets that binds and regulates within
4 the cardiac cells. In a previous study, where we characterized five arrhythmogenic CaM
5 missense mutations we provided biochemical evidence suggesting that one CPVT- (N54I) and
6 two LQTS-associated (D96V and D130G) lead to a defective CaM-RyR2 binding and
7 regulation.⁶ Our findings were in overall agreement with the results of another study, which
8 showed that these mutations markedly reduce inhibition of RyR2 Ca²⁺ release during store
9 overload-induced Ca²⁺ release.²⁶ Moreover, we proposed that another LQTS-associated CaM
10 mutation (F142L) had no apparent effect on RyR2 activity.⁶ This again was consistent with
11 another study that showed that F142L CaM mutation does not impair the CaM-dependent
12 inhibition of RyR2.²³ We previously proposed that the clinical presentation of CPVT or
13 LQTS associated with arrhythmogenic CaM mutations may involve both altered intrinsic Ca²⁺-
14 binding as well as defective interaction with RyR2.⁶ In a similar fashion, Sondergaard et al.
15 also suggested that the regulation of RyR2 Ca²⁺ release is highly sensitive and that aberrant
16 regulation of RyR2 may be a common component of both CPVT and LQTS arrhythmias caused
17 by CaM mutations.²⁶ It is possible that the LQTS-associated CaM mutations that diminish the
18 CaM-RyR2 interaction; and thus inhibition of the open probability of the channel, may
19 contribute to LQTS phenotypes due to the increased RyR2 Ca²⁺ release. It is also very likely
20 that in some cases the altered intrinsic Ca²⁺-binding of CaM triggered by the arrhythmogenic
21 mutation, could indeed potentially affect in a higher degree the function of other ion channel
22 complexes in the cardiac cellular arena, and the effect on RyR2 might be more secondary.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 In conclusion, taking into consideration the deleterious effects of the several currently
50 identified arrhythmogenic CaM mutations on the normal function of the RyR2 as well as of the
51 other ion channels in cardiac cells, further investigation is required to delineate the molecular
52 mechanisms that CaM mutations lead to life-threatening arrhythmogenic cardiac disease.
53 Establishing a mechanistic link between individual CaM mutants and disease pathogenesis
54
55
56
57
58
59
60

1
2
3 might provide the clinicians the evidence needed to stratify their patient population and select
4
5 optimal antiarrhythmic treatment strategies to improve survival of high risk patients. Finally,
6
7 genetic screening for *CALM* mutations should be recommended and performed in young
8
9 individuals presented with arrhythmogenic cardiac disorders.
10
11
12
13
14

15 **Acknowledgements-Funding**

16 M.N. was supported by a QU internal grant ‘QUST-CMED-SPR-2017-8’. A.T. was supported
17
18 from the State Scholarship Foundation (IKY) through the “IKY Fellowships of Excellence for
19
20 Post-Doctoral Research Program” MIS – 5001512.
21
22

23 **Author Contributions**

24 M.N. and F.A.L. devised the project strategy. S.I.D., A.T., K.B., G.K.N., B.S.G., E.T., G.N.,
25
26 F.A.L. and M.N. designed/analyzed the experiments, which were performed by S.I.D., A.T.,
27
28 R.S., B.L.C., K.B., I.C., A.S., A.A. and M.N. Finally, M.N. prepared the first manuscript draft,
29
30 which was revised and approved by all authors.
31
32

33 **Conflicts of Interest**

34 The authors have no conflicts of interest to disclose.
35
36
37
38

39 **References**

- 40
41 1. Ikura, M. & J.B. Ames. 2006. Genetic polymorphism and protein conformational plasticity in
42 the calmodulin superfamily: two ways to promote multifunctionality. *Proc Natl Acad Sci U S A.* **103**:
43 1159-1164.
- 44
45 2. Yamniuk, A.P. & H.J. Vogel. 2004. Calmodulin's flexibility allows for promiscuity in its
46 interactions with target proteins and peptides. *Mol Biotechnol.* **27**: 33-57.
- 47
48 3. Tadross, M.R., I.E. Dick & D.T. Yue. 2008. Mechanism of local and global Ca²⁺ sensing by
49 calmodulin in complex with a Ca²⁺ channel. *Cell.* **133**: 1228-1240.
- 50
51 4. Zhang, M., C. Abrams, L. Wang, *et al.* 2012. Structural basis for calmodulin as a dynamic
52 calcium sensor. *Structure.* **20**: 911-923.
- 53
54 5. Sorensen, A.B., M.T. Sondergaard & M.T. Overgaard. 2013. Calmodulin in a heartbeat. *Febs J.*
55 **280**: 5511-5532.
- 56
57 6. Vassilakopoulou, V., B.L. Calver, A. Thanassoulas, *et al.* 2015. Distinctive malfunctions of
58 calmodulin mutations associated with heart RyR2-mediated arrhythmic disease. *Biochim Biophys*
59 *Acta.* **1850**: 2168-2176.
- 60
61 7. Van Petegem, F. 2012. Ryanodine receptors: structure and function. *J Biol Chem.* **287**:
31624-31632.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. Yang, Y., T. Guo, T. Oda, *et al.* 2014. Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is arrhythmogenic and occurs in heart failure. *Circ Res.* **114**: 295-306.
9. Balshaw, D.M., L. Xu, N. Yamaguchi, *et al.* 2001. Calmodulin binding and inhibition of cardiac muscle calcium release channel (ryanodine receptor). *J Biol Chem.* **276**: 20144-20153.
10. Yamaguchi, N., N. Takahashi, L. Xu, *et al.* 2007. Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. *J Clin Invest.* **117**: 1344-1353.
11. Nyegaard, M., M.T. Overgaard, M.T. Sondergaard, *et al.* 2012. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. *Am J Hum Genet.* **91**: 703-712.
12. Crotti, L., C.N. Johnson, E. Graf, *et al.* 2013. Calmodulin mutations associated with recurrent cardiac arrest in infants. *Circulation.* **127**: 1009-1017.
13. Makita, N., N. Yagihara, L. Crotti, *et al.* 2014. Novel calmodulin mutations associated with congenital arrhythmia susceptibility. *Circ Cardiovasc Genet.* **7**: 466-474.
14. Marsman, R.F., J. Barc, L. Beekman, *et al.* 2014. A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence. *J Am Coll Cardiol.* **63**: 259-266.
15. Boczek, N.J., N. Gomez-Hurtado, D. Ye, *et al.* 2016. Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141G. *Circ Cardiovasc Genet.* **9**: 136-146.
16. Gomez-Hurtado, N., N.J. Boczek, D.O. Kryshal, *et al.* 2016. Novel CPVT-Associated Calmodulin Mutation in CALM3 (CALM3-A103V) Activates Arrhythmogenic Ca Waves and Sparks. *Circ Arrhythm Electrophysiol.* **9**.
17. Takahashi, K., T. Ishikawa, N. Makita, *et al.* 2017. A novel de novo calmodulin mutation in a 6-year-old boy who experienced an aborted cardiac arrest. *HeartRhythm Case Rep.* **3**: 69-72.
18. Nomikos, M., A. Thanassoulas, K. Beck, *et al.* 2014. Altered RyR2 regulation by the calmodulin F90L mutation associated with idiopathic ventricular fibrillation and early sudden cardiac death. *FEBS Lett.* **588**: 2898-2902.
19. Wang, Q., K.C. Liang, A. Czader, *et al.* 2011. The effect of macromolecular crowding, ionic strength and calcium binding on calmodulin dynamics. *PLoS Comput Biol.* **7**: e1002114.
20. Sondergaard, M.T., A.B. Sorensen, L.L. Skov, *et al.* 2015. Calmodulin mutations causing catecholaminergic polymorphic ventricular tachycardia confer opposing functional and biophysical molecular changes. *FEBS J.* **282**: 803-816.
21. VanScyoc, W.S., B.R. Sorensen, E. Rusinova, *et al.* 2002. Calcium binding to calmodulin mutants monitored by domain-specific intrinsic phenylalanine and tyrosine fluorescence. *Biophys J.* **83**: 2767-2780.
22. Yamaguchi, N., L. Xu, D.A. Pasek, *et al.* 2003. Molecular basis of calmodulin binding to cardiac muscle Ca(2+) release channel (ryanodine receptor). *J Biol Chem.* **278**: 23480-23486.
23. Sondergaard, M.T., Y. Liu, K.T. Larsen, *et al.* 2017. The Arrhythmogenic Calmodulin p.Phe142Leu Mutation Impairs C-domain Ca²⁺ Binding but Not Calmodulin-dependent Inhibition of the Cardiac Ryanodine Receptor. *J Biol Chem.* **292**: 1385-1395.
24. Wu, H.H., C. Brennan & R. Ashworth. 2011. Ryanodine receptors, a family of intracellular calcium ion channels, are expressed throughout early vertebrate development. *BMC Res Notes.* **4**: 541.
25. Perez, C.G., J.A. Copello, Y. Li, *et al.* 2005. Ryanodine receptor function in newborn rat heart. *Am J Physiol Heart Circ Physiol.* **288**: H2527-2540.
26. Sondergaard, M.T., X. Tian, Y. Liu, *et al.* 2015. Arrhythmogenic Calmodulin Mutations Affect the Activation and Termination of Cardiac Ryanodine Receptor-mediated Ca²⁺ Release. *J Biol Chem.* **290**: 26151-26162.
27. Venetucci, L., M. Denegri, C. Napolitano, *et al.* 2012. Inherited calcium channelopathies in the pathophysiology of arrhythmias. *Nat Rev Cardiol.* **9**: 561-575.

- 1
2
3 28. Laitinen, P.J., K.M. Brown, K. Piippo, *et al.* 2001. Mutations of the cardiac ryanodine receptor
4 (RyR2) gene in familial polymorphic ventricular tachycardia. *Circulation*. **103**: 485-490.
5 29. Lahat, H., E. Pras & M. Eldar. 2003. RYR2 and CASQ2 mutations in patients suffering from
6 catecholaminergic polymorphic ventricular tachycardia. *Circulation*. **107**: e29; author reply e29.
7 30. Roux-Buisson, N., M. Cacheux, A. Fourest-Lieuvain, *et al.* 2012. Absence of triadin, a protein of
8 the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human.
9 *Hum Mol Genet*. **21**: 2759-2767.
10 31. Amin, A.S., Y.M. Pinto & A.A. Wilde. 2013. Long QT syndrome: beyond the causal mutation. *J*
11 *Physiol*. **591**: 4125-4139.
12 32. Limpitikul, W.B., I.E. Dick, R. Joshi-Mukherjee, *et al.* 2014. Calmodulin mutations associated
13 with long QT syndrome prevent inactivation of cardiac L-type Ca(2+) currents and promote
14 proarrhythmic behavior in ventricular myocytes. *J Mol Cell Cardiol*. **74**: 115-124.
15 33. Hwang, H.S., F.R. Nitu, Y. Yang, *et al.* 2014. Divergent regulation of ryanodine receptor 2
16 calcium release channels by arrhythmogenic human calmodulin missense mutants. *Circ Res*. **114**:
17 1114-1124.
18 34. Yin, G., F. Hassan, A.R. Haroun, *et al.* 2014. Arrhythmogenic calmodulin mutations disrupt
19 intracellular cardiomyocyte Ca²⁺ regulation by distinct mechanisms. *J Am Heart Assoc*. **3**: e000996.
20 35. Wang, K., C. Holt, J. Lu, *et al.* 2018. Arrhythmia mutations in calmodulin cause
21 conformational changes that affect interactions with the cardiac voltage-gated calcium channel. *Proc*
22 *Natl Acad Sci U S A*. **115**: E10556-E10565.
23
24
25
26
27

28 Table Legends

29
30 **Table 1.** Dissociation constants and free energy changes of Ca²⁺ binding to C- (ex: 277 nm,
31 em: 320 nm) and N- domain sites (ex: 250 nm, em: 280 nm) at 25 °C, resolved from fitting of
32 a model-independent two-site Adair function to the experimental data.
33
34
35
36

37 Figure Legends

38
39 **Figure 1.** Zebrafish embryos were injected at one cell stage with cRNA encoding CaM^{WT} and
40 CaM^{E105A} mutant. (A) Representative images of 3-day-old zebrafish (left panel) and zebrafish
41 hearts (right panel) corresponding to uninjected, CaM^{WT} and CaM^{E105A} cRNA-injected groups.
42 (B) Heart rate was analyzed using Danioscope software of captured videos for zebrafish larvae
43 at 3 days old. Representative graphs showing the average of heartbeats per minute for
44 uninjected, CaM^{WT} and CaM^{E105A} cRNA-injected groups, respectively. Error bars represent
45 sample standard error of the mean (SEM). (n=18 analyzed per group). **p ≤ 0.01.
46
47
48
49
50
51
52

53 **Figure 2.** Cardiac activity % was calculated from oscillations in the cardiac signal, with
54 corresponding peaks and lows at regular intervals over time of a total of 6 seconds. Uninjected
55 zebrafish and CaM^{WT} groups exhibited the same pattern of oscillations at approximately 2.5
56 lows per second, while CaM^{E105A} injection resulted in arrhythmia evident by altered oscillations
57 at a pattern of 2 lows and 3 lows per consecutive two seconds.
58
59
60

1
2
3 **Figure 3.** (A) Affinity-purified CaM^{WT} (left panel) and CaM^{E105A} (right panel) recombinant
4 proteins (1 μ g) were analyzed by 15% SDS-PAGE followed by either Coomassie Brilliant Blue
5 staining or immunoblot analysis using an anti-CaM rabbit monoclonal antibody (1:10,000
6 dilution). (B) Far-UV CD spectra and thermal stability of CaM^{WT} and CaM^{E105A} mutant. (I)
7 Spectra were recorded at 4 °C in the presence of 1 mM CaCl₂ (CaM^{WT} green; CaM^{E105A} blue)
8 and 1 mM EDTA (CaM^{WT} orange; CaM^{E105A} red). (II) Thermal denaturation curves are shown;
9 lines represent fits assuming a three-state transition. (III) The histogram summarizes melting
10 temperatures (top panel) and van't Hoff's enthalpies (lower panel) resulting from the data
11 shown in (II).
12
13
14
15
16
17
18
19

20 **Figure 4.** Normalized fluorescence emission intensity profiles of CaM^{WT} (●) and CaM^{E105A}
21 mutant (●) N- (left panel) and C-domain (right panel) as a function of free [Ca²⁺]. Dashed lines
22 represent the nonlinear least-squares fit of a two-site model-independent Adair function to the
23 collected data. (B) Molecular model of CaM E105A mutation revealing that E105 residue is
24 directly involved in the Ca²⁺ binding of CaM. Overlap of wild type (blue) and CaM E105A
25 (red) energy-minimized models of the EF-hand III binding site with key residues shown as
26 sticks. The model is based on PDB entry 1CLL. Ca²⁺ ions are shown as spheres with their Van-
27 der-Waals radii for emphasis.
28
29
30
31
32
33
34
35

36 **Figure 5.** (A) Co-immunoprecipitation assays showing the association of CaM^{WT} and
37 CaM^{E105A} mutant with cardiac RyR2. Native RyR2 was immunoprecipitated specifically with
38 Ab¹⁰⁹³ from CHAPS-solubilized cardiac SR membranes in the presence of 1 μ M CaM^{WT} or
39 CaM^{E105A} mutant at different Ca²⁺ concentrations (0, 1 and 10 μ M). The presence of RyR2-
40 precipitated CaM proteins was analyzed by 18% SDS-PAGE followed by immunoblot
41 detection analysis using an anti-CaM rabbit monoclonal antibody (1:10,000 dilution).
42 Densitometric analysis and normalization was performed following three independent
43 experiments using three different porcine cardiac SR preparations (histograms). (B) Effect of
44 CaM^{E105A} mutant on [³H]ryanodine binding to cardiac SR vesicles. The binding buffer
45 contained 50 mM HEPES, 25 mM Tris, 500 mM KCl, pH 7.4 with either 1 mM EGTA (<0.01
46 μ M Ca²⁺) or with the indicated series of free Ca²⁺ concentrations. Normalized [³H]ryanodine
47 binding data are means \pm SEM of 4 independent experiments.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Tables**

4
5 **Table 1**

6
7
8
9
10
11
12
13

		Apparent Dissociation Constant (K_d)	ΔG_1	ΔG_2	ΔG_c
		μM	kJ/mol	kJ/mol	kJ/mol
CaM^{WT}	C-Domain	2.97 ± 0.03	-28.4 ± 0.2	-63.1 ± 0.1	-9.8 ± 0.3
	N-Domain	8.08 ± 0.09	-28.7 ± 0.2	-58.2 ± 0.1	-4.3 ± 0.3
CaM^{E105A}	C-Domain	28.7 ± 0.03	-26.6 ± 0.2	-51.8 ± 0.2	-2.2 ± 0.4
	N-Domain	8.10 ± 0.10	-28.6 ± 0.2	-58.1 ± 0.1	-4.3 ± 0.3

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

338x142mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2

338x186mm (150 x 150 DPI)




Figure 3

191x160mm (150 x 150 DPI)




Figure 4

211x190mm (150 x 150 DPI)




Figure 5

254x187mm (150 x 150 DPI)